A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

MPS IV AMucopolysaccharidosis IVAMorquio A Syndrome

Interventions

DRUG

BMN 110

Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.

Trial Locations (4)

Birmingham

Dumfries

London

Manchester